Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ELU643
- Development stage
- Preclinical
- Lead developer
- Eluciderm
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
ELU643 is a small molecule inhibitor of poly(ADP-ribose) polymerase (PARP) currently under development by Eluciderm. It is identified as a National Cancer Institute (NCI) candidate molecule, alongside other compounds in the ELU series. The drug is being investigated for its therapeutic potential in treating hematologic malignancies, specifically leukemia, and solid tumors, specifically malignant melanoma. By inhibiting PARP enzymes, ELU643 disrupts the DNA damage response (DDR) pathway, preventing the repair of single-strand DNA breaks and leading to genomic instability and selective apoptosis in rapidly dividing cancer cells.
- Other names
- ELU643ELU-643ELU 643
02
Targets
PARP1 (Poly (adp-ribose) polymerase 1)
Beyond the preview
Go deeper on ELU643.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ELU643.